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Abstract
Background: Within the general population, levels of C-reactive protein (CRP) are positively associated with atherosclerotic
cardiovascular disease (CVD). Whether CRP is causally implicated in atherogenesis or is the results of atherosclerosis is
disputed. A role of CRP to protect endothelium-derived nitric oxide (EDNO) has been suggested. We examined the
association of CRP with EDNO-dependent vasomotor function and subclinical measures of atherosclerosis and
arteriosclerosis in patients with raised CRP resulting from rheumatoid arthritis (RA).
Methodology/Principal Findings: Patients with RA (n=59) and healthy control subjects (n=123), underwent measures of
high sensitivity CRP, flow-mediated dilation (FMD, dependent on EDNO), intima-media thickness (IMT, a measure of
subclinical atherosclerosis) and aortic pulse wave velocity (PWV, a measure of arteriosclerosis). IMT and PWV were elevated
in patients with RA compared to controls but FMD was similar in the two groups. In patients with RA, IMT and PWV were not
correlated with CRP but FMD was positively independently correlated with CRP (P,0.01).
Conclusions/Significance: These findings argue against a causal role of CRP in atherogenesis and are consistent with a
protective effect of CRP on EDNO bioavailability.
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Introduction
C-reactive protein (CRP), a biomarker of systemic inflammation,
independently associates with endothelial dysfunction, subclinical
atherosclerosis and arteriosclerosis[1,2] and clinical manifestations of
atherosclerosis in the general population[3,4]. CRP has been
advocated for use in prediction of cardiovascular disease (CVD)
risk[5,6]. It has been suggested that systemic inflammation leads to
endothelial activation and dysfunction and that CRP itself may be a
causal factor in atherogenesis[7,8]. It is notable that reduction of CRP
bya statin inthosewithlow/normalLDLisassociated with amarked
reduction in CVD events[9]. However, it is also possible that CRP is
produced by inflammation within atherosclerotic plaque and
therefore associates with atherosclerosis by reverse causality[10]. It
is thus important to clarify, whether when raised levels of CRP arise
from a non-vascular cause (i.e. a stimulus for CRP other than
atherosclerosis), CRP retains its association with CVD. This would
validate the potential use of CRP for risk assessment irrespective of
co-morbidity and/or the cause of raised CRP, and would add weight
to the putative causal role of CRP in CVD.
Rheumatoid arthritis (RA) is a chronic inflammatory condition
associated with subclinical vascular disease and a greater
prevalence of CVD than can be accounted for by traditional risk
factors alone; compared to controls, the relative risk of myocardial
infarction in RA is doubled[11]. CRP in RA is usually increased
into the range associated with increased CVD risk[12] raising the
possibility that CRP is responsible for accelerated atherogenesis in
RA. The purpose of the present study was to examine the
association of CRP with vascular function and structure in RA to
determine if CRP is likely to be a useful marker of sub-clinical
atherosclerosis and increased CVD risk in RA and whether CRP
retains its association with subclinical CVD in a systemic
inflammatory condition where a major stimulus to production of
CRP arises from inflammation outwith atherosclerotic plaques.
We examined endothelial function (by flow mediated dilation,
FMD, a measure of EDNO), intima-media thickness (IMT, a
measure of subclinical atherosclerosis) and large artery stiffness by
pulse wave velocity (PWV, a measure of arteriosclerosis). These
measures of subclinical CVD are all strongly predictive of
CVD[13–26].
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Patients with RA (n=65, complete data subsequently available
in n=59) fulfilling the American College of Rheumatology
classification criteria[27] were recruited from the rheumatology
clinics of Guy’s and St Thomas’ NHS Foundation Trust Hospital.
Patients had not previously been treated with biological agents
(e.g. TNF-a antagonists). Patients were excluded if they had
evidence of: inter-current infections; coronary heart disease;
cerebrovascular disease; peripheral disease; diabetes mellitus, or
if they were receiving HMG-coA reductase inhibitors (statins) or
aspirin. Healthy age matched controls (n=123) recruited from the
local community were studied contemporaneously. The study was
approved by the Guy’s and St Thomas’ NHS Foundation Trust
Research Ethics Committee. All subjects gave written informed
consent.
Protocol
Subjects attended in the morning, having refrained from
caffeine and alcohol for 12 hours, and vascular measurements
were made in a quiet temperature controlled laboratory after a
standardised light breakfast. Blood pressure was measured seated
using an automated oscillometric device (Omron HEM 705,
Omron, Japan). Blood for biochemistry was obtained after an
overnight fast on a day prior to (and within 8 weeks) of the vascular
measurements. CRP was measured using high-sensitivity turbidi-
metric immunoassay (WAKO Chemicals) on a Cobas Mira
Analyser (Roche Diagnostics).
Endothelial function
Endothelial function was assessed by measuring FMD of the
brachial artery[28] according to current guidelines. High resolution
ultrasound (Aspen, Siemens, Germany with 7 MHz linear array
transducer, positioned by a stereotactic manipulator) was used to scan
the brachial artery in a longitudinal section 2 to 15 cm above the
elbow. After optimal positioning of the transducer a baseline scan was
recorded. Increased flow was then induced by inflation of a
pneumatic tourniquet placed around the forearm (distal to the
arterial segment being scanned) to a pressure of 250 mmHg for
5 min, followed by release. A second scan commenced 10 sec before
release of the cuff and continued for 3 min after cuff deflation. After
10 min to allow vessel recovery, another resting scan was taken.
Sublingualnitroglycerine(NTG,25 mg) was then administered, and a
f i n a ls c a np e r f o r m e d3t o4m i nl a t e r .I m a g e sw e r ec o d e da n d
recorded on VHS videotape, then digitized for subsequent blinded
analysis using automated edge detection software (Brachial Analyser,
Medical Imaging Applications, LCC, Iowa, USA). FMD was
expressed as the percentage increase in brachial artery diameter
from baseline to maximal dilation which occurred 30 to 90 sec after
release of the cuff. Dilation to NTG was expressed as the percentage
increase inbrachialartery diameterfrombaseline to maximaldilation
after NTG.
Common carotid intima-media thickness
High resolution ultrasound (as for FMD) was used to image the
left and right common carotid arteries. IMT was measured from
digitized images obtained in diastole of the near and far walls of
both common carotid arteries 1–2 cm proximal to the flow
divider. This method provides a robust measure of IMT with
reproducibility higher than that in other segments[19].
Carotid-femoral pulse wave velocity
PWV was measured over the carotid-femoral portion of the
arterial tree by ECG referenced sequential carotid and femoral
tonometry using the SphygmoCor system (Atcor, Australia).
Transit time was measured from the foot to foot delay between
the carotid and femoral pulse waveforms. Carotid-femoral
distance was estimated from the distance between the suprasternal
notch and the femoral artery at the site of transducer placement.
All measurements were made by an experienced observer and
readings which did not conform to the internal quality checks
provided by the SphgmoCor software were rejected. Measure-
ments were made in triplicate with mean values used for analysis.
Statistical analyses
There were 6 subjects with incomplete data in the RA group
(due to errors in laboratory handling of samples) and the analysis
was restricted to n=59 in whom complete data were available.
The relation between vascular measures and risk factors other
than CRP was examined (in each group separately and in the
combined groups) by univariate regression analysis. Vascular
measures were compared in the RA and control groups by analysis
of covariance, incorporating potential confounding values identi-
fied on the univariate analysis. The relationship between vascular
measures and CRP within the RA group was examined by
regression analysis with CRP treated both as a continuous variable
and with CRP categorised into tertiles as an ordinal variable. All
potential confounding variables indentified on univariate analysis
were again incorporated as co-variates. Analyses were performed
using SPSS for Windows version 17 and P,0.05 was considered as
evidence against the null hypothesis.
Results
Subject characteristics
Subject characteristics (RA n=59, healthy controls n=123) are
shown in Table 1. Within the RA group, compared to the control
group, there were fewer men, mean values of BMI were lower,
blood pressure higher and HDL-cholesterol lower (table 1). 20% of
RA subjects were current smokers. CRP was higher in RA patients
(median 9.10 mg/l, IQR 5.00–17.30) compared to controls
(median 0.30 mg/l, IQR 0.04–1.22, P,0.0001).
Relation of vascular measures to risk factors other than
CRP
Within the control group and the combined groups, measures of
vascular function and structure were associated with classical risk
factors for atherosclerosis, most strongly with age and systolic
blood pressure. On multivariate analysis, in the combined groups,
FMD was independently negatively associated with age (P,0.01),
systolic blood pressure (P,0.05) and tended to be negatively
associated with total cholesterol (P,0.1). IMT was independently
associated with age (P,0.001) and systolic blood pressure
(P,0.01). PWV was independently associated with age
(P,0.001) and systolic blood pressure (p,0.001).
Comparison of vascular measures in RA and control
groups
When adjusted for all potential confounding factors found to be
correlated with vascular measures on univariate analysis (P,0.05),
FMD was not different between RA and control groups
(6.2260.33% vs. 6.5560.22%, means 6SEM, P=NS). Results
were similar when the analysis was restricted to non-smokers
(6.3060.37% vs. 6.6060.21%, P=NS). IMT was greater in RA
compared to control subjects (0.9060.03 mm vs. 0.8260.01 mm,
P,0.05). PWV was also greater in RA compared to control
subject (8.6960.18 m/s vs. 8.0260.12 m/s, P,0.01).
CRP Rheumatoid Arthritis
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Within the RA group, FMD was positively associated with CRP
(P,0.01, by multiple regression analysis incorporating age, sex,
body mass index, smoking status, systolic blood pressure, total
cholesterol and high density lipoprotein, disease activity, disease
duration and concurrent drug treatment). FMD also positively
correlated with CRP in non-smokers with RA (P,0.05) on
multivariate regression analysis. IMT and PWV were not
associated with CRP (Figure 1). There was no relationship
between vascular measures and disease duration/activity as
measured by disease activity score, nor with the health assessment
questionnaire score. These findings were similar irrespective of
whether the analysis was performed using CRP as a continuous
variable or categorized into tertiles.
Discussion
We devised our study to investigate if raised CRP occurring in
a chronic inflammatory disease associates with subclinical CVD.
This was for two reasons. Firstly if CRP is to be useful in CVD
risk prediction in patients with chronic inflammatory disease, a
close association between CRP and CVD would be mandated,
and secondly, if CRP is causal in CVD, a raised CRP from
whatever cause should associate with CVD. Contrary to what
might be expected, in patients with elevated CRP due to chronic
disease activity in RA, IMT and PWV, structural measures of
early atherosclerosis/arteriosclerosis, were not related to CRP
and, intriguingly, the reverse association was found for FMD:
higher CRP levels correlated with higher FMD i.e. higher levels
of CRP were associated with better, not worse, endothelial
function. This association remained robust when potentially
confounding factors such as disease duration, activity of disease
and concurrent drug treatment were controlled for. As far as we
are aware, this is the first study to report such a paradoxical
association between FMD and CRP in subjects with a chronic
inflammatory condition.
These findings are difficult to reconcile with CRP as a causal
factor in CVD. The findings with respect to IMT and PWV are,
however, consistent with the association between CRP and CVD
being driven by reverse causality (i.e. CVD causing raised CRP).
Values of CRP in the mid and upper tertiles of the distribution in
patients with RA were greater than those found in subjects with
subclinical CVD but without another stimulus to CRP production
(such as RA). Thus a lack of association between CRP and CVD
would be expected in RA if CRP arising from a stimulus unrelated
Table 1. Characteristics of rheumatoid arthritis patients and healthy controls.
Controls (n=123) Rheumatoid arthritis (n=59)
CRP #5 mg/L
(n=20)
CRP 5 to 13 mg/L
(n=19)
CRP .13 mg/L
(n=20)
Age (mean years 6 SD) 48.9769.87 50.8568.63 51.32610.54 49.20614.04
Sex (females, %) 73 (59.35) 15 (75.00) 17 (89.47) 16 (80.00)
BMI (mean kg/m
2 6 SD) 27.7263.90{ 24.1263.19 26.1667.28 26.3466.64
Present smokers (number, %) 0 6 (30.00) 4 (21.05) 2 (10.00)1
Systolic blood pressure (mean mmHg 6 SD) 117.59615.08 122.58619.02 126.00614.84 126.53615.90
Diastolic blood pressure (mean mmHg 6 SD) 73.4768.12 77.5969.60 77.2168.78 76.5768.08
Total cholesterol (mean mmol/l 6 SD) 5.4061.02* 5.3060.97 5.5761.02* 4.7060.82
HDL-cholesterol (mean mmol/l 6 SD) 1.5160.40* 1.4460.42* 1.3760.41 1.1260.23
LDL-cholesterol (mean mmol/l 6 SD) 3.3660.83 3.4460.85 3.7260.90 3.0660.78
TG (mean mmol/l 6 SD) 1.2860.69{ 0.8760.37 1.0460.48 1.1060.49
CRP (median mg/l, IQR) 0.30 (0.04, 1.22) 3.35 (2.40, 5.00) 9.10 (7.20, 10.90) 25.85 (16.65, 39.40)
Rheumatoid arthritis disease parameters
Disease duration (median years 6 IQR) - 9.00 (2.00, 20.00) 12.50 (2.00, 19.50) 9.00 (3.00, 21.00)
Disease Activity Score (mean 6 SD) - 3.9061.53 5.1361.19{ 5.7861.10{
Health Assessment Questionnaire (mean 6 SD) - 0.9360.77 1.6460.94{ 1.7860.81{
Drug therapy{
Methotrexate (no, %) - 10 (50.00) 15 (78.95) 16 (80.00)
Sulphasalazine (no, %) - 7 (35.00) 10 (52.63) 8 (40.00)
Hydroxychloroquine (no, %) - 2 (10.00) 6 (31.58) 4 (20.00)
Leflunamide (no, %) - 2 (10.00) 3 (15.79) 0
Gold (no, %) - 1 (5.00) 0 0
NSAIDs (including cyclo-oxygenase 2 inhibitors, no, %) - 1 (5.00) 6 (31.57) 10 (50.00)
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglycerides; CRP: C-reative protein; NSAIDs: non-steroid anti-inflammatory drugs;
SD: standard deviation; IQR: interquartile range.
{No patient with rheumatoid arthritis received azathioprine treatment at the time of enrolment to the study.
*P,0.05 compared to 3
rd (.13 mg/L) CRP tertile.
{P,0.05 compared to 1
st (#5 mg/L) CRP tertile.
1distribution of smoking in RA patients P=0.29 (Fisher’s exact test).
Rheumatoid arthritis patients are grouped into tertile of C-reactive protein.
doi:10.1371/journal.pone.0010242.t001
CRP Rheumatoid Arthritis
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epidemiological studies support such reverse causality[29–33].
Reverse causality in the link between CRP and CVD would not
explain the apparent paradoxical association of FMD and CRP
seen in the present study with better FMD associated with higher
levels of CRP. Unlike IMT and PWV which are structural changes
associated with early atherosclerosis/arteriosclerosis in the suben-
dothelial arterial wall, FMD is a measure of endothelial cell
function. Although generally regarded as a surrogate for
generalized endothelial cell function,[34] FMD is mainly deter-
mined by the availability of EDNO[35] which, as well as
regulating arterial tone, has antiatherogenic functions[36,37]. In
the presence of Reactive Oxygen Species, NO can be deleterious
to the endothelium[38], yet FMD measures the vasodilatory
(protective) function of EDNO in response to shear stress of the
vessel wall[28]. It is notable that previous studies show that pure
human CRP has specific, direct effects on vascular function in
vitro via increased NO production[39] and that following an acute
inflammatory insult, NO-dependent vasodilator function is
immediately impaired but returns to normal when CRP rises[39].
Our findings are entirely consistent with such a protective role of
CRP on NO availability and hence FMD. They may explain why
FMD is not always impaired in subjects with RA compared with
healthy control subjects[40]. A protective effect of CRP on NO
availability would be expected to abrogate adverse effects of
systemic inflammation on aspects of atherogenesis other than those
dependent on NO and suggests that these may be partially masked
by the increased CRP associated with inflammation. Of note,
prospective studies have demonstrated that CRP is associated with
cardiovascular end-points in RA[41,42]. With prevalent CVD, CRP
may be a by-product of atherosclerosis and its association could
result from reverse causation; our study could not demonstrate this
as our RA patients had not experienced incident CVD. An
alternative explanation, by analogy to NO[38], is that CRP may
have pleiotropic roles, some protective and others harmful.
These data are of relevance to CVD prevention through
reduction in inflammation. In the general population, targeting
individuals with raised CRP for statin therapy reduces CVD
events[9] and it has been suggested that these results can be
extrapolated to subjects with chronic autoimmune disease such as
RA[43]. Our findings suggest that the use of CRP in RA (and
perhaps other chronic inflammatory disease) should be further
evaluated before being used as a risk marker of CVD.
Our study was limited in several ways. The cross-sectional
design does not provide definitive evidence of causality or reverse
causality although, as discussed above, the results do strongly
argue against a detrimental effect of CRP on all aspects of
endothelial dysfunction and atherosclerosis, particularly those
involving NO availability. We measured vascular function/
structure and CRP only at a single time point. Temporal variation
of these properties would, however, tend to obscure the most
striking observation in this study: the paradoxical association of
FMD with CRP. Our conclusions relate only to subclinical
measures of CVD: endothelial vasomotor NO-dependent func-
tion, intima-media thickening and arterial stiffening. Although
each of these measures is strongly related to clinical CVD they are
not the only determinants of CVD events. Results relating to
atherosclerosis and CVD mortality in relation to CRP in RA are
conflicting[41,42,44] and CRP could have a role relating to
thrombogenesis independent of atherogenesis[7].
In conclusion, CRP in patients with RA is unrelated to
structural measures of subclinical arterial disease and there is a
paradoxical association of CRP with improved endothelial
function. These observations argue against a causal role of CRP
in atherosclerosis. They are consistent with reverse causality in the
association of CRP with atherosclerosis and a protective effect of
CRP on NO availability. Further studies are warranted to
determine if there is a dissociation of CRP with clinical CVD
events in chronic inflammatory conditions and interventional
studies are required to determine if there are potential protective
effects of CRP on aspects of endothelial function.
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